GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (ASX:BLT) » Definitions » Cyclically Adjusted PB Ratio

Benitec Biopharma (ASX:BLT) Cyclically Adjusted PB Ratio : (As of Jun. 14, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Benitec Biopharma Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Benitec Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Benitec Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Cyclically Adjusted PB Ratio Chart

Benitec Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Benitec Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 0.03

Competitive Comparison of Benitec Biopharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Benitec Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Benitec Biopharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Cyclically Adjusted PB Ratio falls into.



Benitec Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Benitec Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Benitec Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.055/131.7762*131.7762
=0.055

Current CPI (Mar. 2024) = 131.7762.

Benitec Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201312 0.000 98.326 0.000
201406 0.208 100.560 0.273
201412 0.251 99.070 0.334
201503 0.000 99.621 0.000
201506 0.203 100.684 0.266
201509 0.000 100.392 0.000
201512 0.185 99.792 0.244
201603 0.171 100.470 0.224
201606 0.128 101.688 0.166
201609 0.134 101.861 0.173
201612 0.102 101.863 0.132
201703 0.116 102.862 0.149
201706 0.105 103.349 0.134
201709 0.089 104.136 0.113
201712 0.078 104.011 0.099
201803 0.063 105.290 0.079
201806 0.071 106.317 0.088
201809 0.000 106.507 0.000
201812 0.107 105.998 0.133
201903 0.000 107.251 0.000
201906 0.093 108.070 0.113
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 0.046 108.767 0.056
202009 0.033 109.815 0.040
202012 0.060 109.897 0.072
202103 0.044 111.754 0.052
202106 0.081 114.631 0.093
202109 0.066 115.734 0.075
202112 0.047 117.630 0.053
202203 0.032 121.301 0.035
202206 0.013 125.017 0.014
202209 0.068 125.227 0.072
202212 0.041 125.222 0.043
202303 0.022 127.348 0.023
202306 0.001 128.729 0.001
202309 0.108 129.860 0.110
202312 0.072 129.419 0.073
202403 0.055 131.776 0.055

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Benitec Biopharma  (ASX:BLT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Benitec Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Benitec Biopharma (ASX:BLT) Business Description

Traded in Other Exchanges
Address
3940 Trust Way, Hayward, CA, USA, 94545
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.

Benitec Biopharma (ASX:BLT) Headlines

From GuruFocus

Blount International Inc. (BLT) CEO International Inc Blount buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 10-01-2009

John Rogers Trims Stake in Blount International

By Kyle Ferguson Kyle Ferguson 04-18-2016

John Rogers Increases Stake in Blount International

By Tiziano Frateschi Tiziano Frateschi 04-13-2015

Jean-Marie Eveillard Sells More Blount International

By Holly LaFon Holly LaFon 10-09-2012

Ariel Fund Quarterly Commentary From John Rogers

By Holly LaFon Holly LaFon 01-21-2016